Sam Milstein News Today

/PRNewswire/ -- Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, announced today the appointment of Stephen Griffin, Ph.D....

/PRNewswire/ -- Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, announced today that it has received U.S. Food and Drug...

Share this article Share this article FREMONT, Calif. and OXFORD, United Kingdom, April 21, 2021 /PRNewswire/ -- Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to conduct a U.S. trial for the Contour Neurovascular System™, indicated for the treatment of intracranial aneurysms. The IDE approval follows the receipt of Breakthro...

Cerus Endovascular Receives FDA Breakthrough Device Designation for its Contour Neurovascular System™ News provided by Share this article Share this article FREMONT, Calif. and OXFORD, United Kingdom, Feb. 11, 2021 /PRNewswire/ -- Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Contour Neurovascular System™. Breakthrough Device Des...

Cerus Endovascular Announces the First Ever Robotic Assist Intracranial Implant of its Contour Intrasaccular Device Groundbreaking Aneurysm Procedure Completed in 28 Minutes News provided by Share this article Share this article FREMONT, Calif. and OXFORD, United Kingdom, Dec. 17, 2020 /PRNewswire/ -- Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced the first ever robotically assisted intracranial implant of its Contour intrasaccular device. ...